Free Trial

Olema Pharmaceuticals (OLMA) SEC Filings & 10K Form

Olema Pharmaceuticals logo
$5.19 -0.11 (-2.08%)
As of 11:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Recent Olema Pharmaceuticals SEC Filings

DateFilerForm TypeView
05/15/2025
7:46 AM
Deep Track Capital, LP (Filed by)
Olema Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
05/15/2025
6:00 AM
Bain Capital Life Sciences Opportunities IV, L.P. (Filed by)
Olema Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
05/13/2025
6:29 PM
Logos Global Management LP (Filed by)
Olema Pharmaceuticals (Subject)
Form SCHEDULE 13D/A
05/13/2025
6:14 PM
Graham G. Walmsley (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4/A
04/28/2025
3:40 PM
Olema Pharmaceuticals (Filer)
Form ARS
04/28/2025
3:30 PM
Olema Pharmaceuticals (Filer)
Form DEF 14A
04/28/2025
3:35 PM
Olema Pharmaceuticals (Filer)
Form DEFA14A
04/15/2025
4:04 PM
BlackRock Portfolio Management LLC (Filed by)
Olema Pharmaceuticals (Subject)
Form SCHEDULE 13G
03/18/2025
3:26 PM
Olema Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/18/2025
3:15 PM
Olema Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/18/2025
3:10 PM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2025
6:15 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/03/2025
3:16 PM
Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
3:18 PM
Mitchell Shawnte (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
3:19 PM
Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
3:20 PM
Myles David C. (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2025
3:45 PM
Olema Pharmaceuticals (Subject)
Paradigm Biocapital Advisors LP (Filed by)
Form SCHEDULE 13G/A
01/15/2025
11:15 PM
Olema Pharmaceuticals (Filer)
Form EFFECT
01/15/2025
11:15 PM
Olema Pharmaceuticals (Filer)
Form EFFECT
01/15/2025
3:44 PM
Olema Pharmaceuticals (Filer)
Form 424B3
01/15/2025
3:46 PM
Olema Pharmaceuticals (Filer)
Form 424B5
01/14/2025
5:38 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2025
3:31 PM
Bain Capital Life Sciences Fund IV, L.P. (Reporting)
Bain Capital Life Sciences Investors, LLC (Reporting)
Bain Capital Life Sciences IV General Partner, LLC (Reporting)
Bain Capital Life Sciences Opportunities IV GP, LLC (Reporting)
Bain Capital Life Sciences Opportunities IV, L.P. (Reporting)
Olema Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
01/13/2025
3:34 PM
Bain Capital Life Sciences Fund IV, L.P. (Reporting)
Bain Capital Life Sciences Investors, LLC (Reporting)
Bain Capital Life Sciences IV General Partner, LLC (Reporting)
Bain Capital Life Sciences Opportunities IV GP, LLC (Reporting)
Bain Capital Life Sciences Opportunities IV, L.P. (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2025
3:24 PM
Bain Capital Life Sciences Opportunities IV, L.P. (Filed by)
Olema Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
01/13/2025
6:15 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/03/2025
3:49 PM
Olema Pharmaceuticals (Filer)
Form S-3
Registration statement under Securities Act of 1933  
12/18/2024
5:52 PM
Graham G. Walmsley (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4/A
12/17/2024
6:52 PM
Graham G. Walmsley (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2024
6:29 PM
Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/13/2024
3:37 PM
Logos Opportunities Fund I LP (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2024
6:56 PM
Myles David C. (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
6:56 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
6:52 PM
Bohen Sean (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
6:53 PM
Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
6:54 PM
Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:19 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2024
4:04 PM
Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2024
3:27 PM
Bohen Sean (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2024
3:30 PM
Bain Capital Life Sciences Opportunities IV, L.P. (Filed by)
Olema Pharmaceuticals (Subject)
Form SC 13G
12/11/2024
3:33 PM
Olema Pharmaceuticals (Subject)
Zojwalla Naseem (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Buffett’s Next Move Could Shock Wall Street (Ad)

In just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next great gold rush. Savvy insiders are quietly positioning now… before Buffett makes it official. Garrett Goggin has already pinpointed four tiny-gold-miners that could 100X once the announcement hits. It’s the perfect moment to be greedy — before the herd wakes up.

Get Garrett’s Top Four gold picks now — before the world’s greatest investor pulls the trigger.
12/10/2024
2:23 PM
Bohen Sean (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/10/2024
1:48 PM
Myles David C. (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/10/2024
1:14 PM
Olema Pharmaceuticals (Subject)
Zojwalla Naseem (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/10/2024
1:21 PM
Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/10/2024
1:38 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/10/2024
6:15 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/02/2024
6:15 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/26/2024
3:48 PM
Graham G. Walmsley (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4/A
11/18/2024
5:00 AM
Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2024
3:34 PM
Olema Pharmaceuticals (Subject)
Paradigm Biocapital Advisors LP (Filed by)
Form SC 13G/A
11/14/2024
8:20 AM
Deep Track Capital, LP (Filed by)
Olema Pharmaceuticals (Subject)
Form SC 13G/A
09/27/2024
6:00 AM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2024
3:15 PM
Olema Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/31/2024
4:15 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/29/2024
3:23 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/12/2024
4:15 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/11/2024
11:59 AM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/02/2024
4:30 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2024
3:30 PM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/02/2024
3:30 PM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/28/2024
2:13 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/18/2024
4:31 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2024
3:39 PM
Olema Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/14/2024
3:34 PM
Olema Pharmaceuticals (Subject)
Point72 Asset Management, L.P. (Filed by)
Form SC 13G
06/06/2024
5:49 PM
Logos Global Management LP (Filed by)
Olema Pharmaceuticals (Subject)
Form SC 13D/A
06/06/2024
9:02 AM
Logos Opportunities Fund I LP (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/06/2024
9:05 AM
Logos Opportunities Fund II LP (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/04/2024
8:00 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2024
2:09 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/03/2024
1:55 PM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/31/2024
11:17 AM
Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:OLMA) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners